Structures of a dimodular nonribosomal peptide synthetase reveal conformational flexibility

Janice M. Reimer[a], Maximilian Eivaskhani[a], Ingrid Harb[a], Alba Guarné[a], Martin Weigt[b] and T. Martin Schmeing[a]

[a]Department of Biochemistry, McGill University, Montréal, QC, Canada, H3G 0B1

[b]Sorbonne Université, CNRS, Institut de Biologie Paris-Seine, Laboratory of Computational and Quantitative Biology, F-75005, Paris, France.

Correspondence e-mail: martin.schmeing@mcgill.ca

1   **Abstract**

2   Nonribosomal peptide synthetases (NRPSs) are biosynthetic enzymes that synthesize natural product

3   therapeutics using a modular synthetic logic, whereby each module adds one aminoacyl substrate to the

4   nascent peptide. We have determined five crystal structures of constructs of linear gramicidin

5   synthetase subunit A, including a structure of the full core dimodule in a conformation organized for

6   the condensation reaction and a high resolution structure showing intermodular peptidyl substrate

7   delivery. The structures reveal massive differences in the relative positions of adjacent modules which

8   are not strictly coupled to the catalytic cycle, and which are consistent with small angle X-ray

9   scattering (SAXS) data. The structures and covariation analysis of homologs allowed us to create

10 mutants which improve the yield of a peptide from a module-swapped dimodular NRPS.

Introduction

Nonribosomal peptide synthetases (NRPSs) are intricate macromolecular machines that make small molecule products with very high chemical diversity and activity (*1*). NRPS compounds have found widespread clinical use as antitumors, antibiotics, antifungals and immunosuppressants, and are on lists of United Nations-designated essential medicines (*2*) and top-selling pharmaceuticals (*3*).

Nonribosomal peptide synthesis proceeds with thiotemplated, modular assembly-line logic where each multi-domain module adds one amino acid substrate to the growing peptide (Fig. 1) (*4*). A module's adenylation (A) domain selects and activates the amino acid, then covalently attaches it as a thioester to the thiolation (T) domain's phosphopantetheine (ppant) arm. The condensation (C) domain catalyzes peptide bond formation between that aminoacyl-T domain and the donor peptidyl-T domain from the upstream module (*5, 6*). The newly elongated peptidyl-T domain is then the donor substrate for condensation in the downstream module, passing off and further elongating the peptide. Many modules also have tailoring domains integrated within them, which co-synthetically modify the nonribosomal peptide, such as the tailoring formylation (F) domain (*7*) found in the initiation module of the NRPS studied here, linear gramicidin synthetase (Fig. 1).

An excellent structural understanding of the synthetic cycle of isolated modules has been gained from structures of domains, didomains, and individual modules (reviewed in (*4, 8*)). However, modules typically function within the context of the full NRPS. They are physically attached to their neighbors by flexible peptide linkers or through small docking domains (*9*). Adjacent modules must functionally coordinate at least once during the synthetic cycle, when the C domain catalyzes peptide bond formation between aminoacyl and peptidyl moieties attached to T domains of adjacent modules. Little else is known about how modules work with each other in the context of the larger NRPS. There are only two previous high-resolution structures that contain domains from adjacent modules: the T_5C_6 didomain of tyrocidine synthetase is in an unproductive conformation (*10*), while $A_1T_1C_2$ of bacillibactin synthetase (*11*) showed that the sole observed intermodule contact must break in the

3

36   course of peptide synthesis. The only 3D data for a multimodular NRPS are our 26-29 Å negative stain

37   electron microscopy reconstructions of two modules of bacillibactin synthetase (CATCAT) which

38   showed heterogeneity in the module:module conformation (*11*). Hypothetical models of multimodular

39   NRPSs can be constructed by consecutively overlapping multi-domain structures from different

40   synthetases, and the models often take the form of rigid superhelices (*4, 12*), but there is no evidence

41   that any of these conformations occur *in vivo*. More data are needed to understand NRPS architecture,

42   organization and intramodular function during the synthetic cycle of an NRPS, and to facilitate their

43   use to make new-to-nature compounds.

44

45   **Results**

46   *LgrA crystallography*

47   Linear gramicidin synthetase is a 16-module, 4-protein NRPS which makes the clinically used

48   eponymous antibiotic (Fig. 1) (*13*). The antibiotic acts by forming dimeric β-helical pores in Gram-

49   positive bacterial membranes, which kills the bacteria by allowing free passage of monovalent cations

50   across the membrane (*14*). To gain insight into outstanding trans- and super-modular questions in

51   NRPS function, we undertook hundreds of thousand crystallography screening trials with constructs of

52   linear gramicidin synthetase subunit A (LgrA, with domains $FATCATE^0$; Fig. 1) complexed with

53   substrates, substrate analogues and dead-end inhibitors. This yielded five structures: two structures of

54   the four-domain construct FATC in peptide donation conformation ($FAT_{fVal}C$ and $FAT_{fVal}C^*$; Fig. 2A,

55   fig. S1A), one of FATCA in peptide donation conformation (FATCA; Fig. 2B), one of FATCA in two

56   thiolation conformations ($FAT_{Vad}CA$; Fig. 2C, D), and one of the full dimodule FATCAT in overall

57   condensation conformation (FATCAT; Fig. 2E) (figs. S1-S2, Table S1). In every structure, each

58   domain assumes its canonical forms (*4, 8*): the F domain bears the formyltransferase catalytic domain

59   fold, the C domain is a V-shaped pseudodimer of chloramphenicol acetyltransferase-like lobes with a

60   tunnel to its active site, each A domain has its major portion which include the amino acid binding site

61   (A$_{core}$) and its mobile C-terminal subdomain (A$_{sub}$), and the PCP domains are small 4-helix bundles

62   with prosthetic ppant arms. As examined below, together these structures of LgrA demonstrate three

63   general features of NRPS architecture: 1. The didomain structural unit (FA$_{core}$ or CA$_{core}$) of an NRPS

64   module largely maintains its overall conformation (*15-19*). 2. The small domains (T and A$_{sub}$) move

65   according to catalytic state (*15-20*). 3. Observed in detail here, the relative orientations of adjacent

66   modules in an NRPS can vary markedly.

67

68   *Conformations within modules*

69   The main structural units of the modules are the FA$_{core}$ or CA$_{core}$ didomains. The current

70   structures include 11 crystallographically independent FA$_{core}$ or CA$_{core}$ didomains, more than doubling

71   the number available (*15-19*) (Fig. 2, 3A). These show the didomains in each module as "catalytic

72   platforms" (*15*) that present the binding site for each module's T domains (the F$_1$ and A$_1$ active sites for

73   T$_1$; the C$_2$ acceptor site and A$_2$ active site for T$_2$) on the same face to facilitate substrate delivery. The

74   didomains are fairly rigid, as the F:A or C:A configurations shift by only ~1-12° degrees, propagating

75   to ~10 Å (Fig. 3, figs. S3-S4). In FATCA, there are few crystal contacts at the distal end of A$_2$, and

76   variation in the C:A$_{core}$ orientation from unit cell to unit cell is evident from progressively increasing B-

77   factors and weaker electron density at the distal end of A$_2$. However, there is substantially more

78   variation in C:A$_{core}$ conformations between different NRPSs than in a single NRPS: A$_{2core}$

79   superimposition with modules of enterobactin, AB3403 and surfactin synthetases places some

80   equivalent C domain residues >20 Å apart, because of variations of the C:A interface and "openness"

81   (*21*) of the V shape of the C domain (figs. S4-S5).

82   The positions of the A$_{sub}$ and T domains do vary depending on catalytic state (Fig. 3A) (*15-20*).

83   As further explored below, T$_1$ is bound at the donor site of C$_2$ in four structures, and in three of these

84   (FAT$_{fVal}$C, FAT$_{fVal}$C* and FATCAT), A$_{1sub}$ is bound to A$_{1core}$ in adenylation conformation (Fig. 2A, B,

85   F). Simultaneously positioning of T$_1$ for condensation and A$_1$ for adenylation reiterates that NRPSs can

5

86   start a second synthetic cycle before finishing the first (Fig. 1) (*18*)). In both $FAT_{Vad}CA$ molecules, T_1

87   and A_{1sub} are bound to A_{1core} in thiolation conformation (Fig. 1, 2D,E) (*17, 22, 23*). This means that

88    $FAT_{fVal}C$ and $FAT_{Vad}CA$ represent consecutive steps in synthesis (Fig. 1). To move between catalytic

89   conformations observed here, A_{sub} rotates up to ~151° and translates up to ~17 Å, and T_1 rotates up to

90   ~153° and translates up to ~47 Å (fig. S5) (*22, 24*). These transitions are as large as those A_{sub} and T_1

91   require to move between their positions in the rest of the synthetic cycle, for example to and from

92   formylation conformation (*17*).

93

94   *The condensation and substrate donation conformation*

95   Condensation is the central chemical event of peptide synthesis. It requires that donor T domain

96   (here T_1) and acceptor T domain (here T_2) bind simultaneously to the C domain (Fig. 4). The structure

97   of FATCAT features the full condensation state, with both T_1 and T_2 bound to C_2, and represents a

98   detailed 3D view of a multi-modular NRPS (Fig. 4A). The resolution of this structure is 6 Å, but the

99   high resolution structures of F_1, A_1, T_1, C_2, A_{2core} and homology models of the ~100 residue A_{2sub} and

100   ~90 residue T_2, enabled the building of a high-quality structure for the full, 1800 residue dimodule (fig.

101   S1). T_2 occupies the acceptor binding site on C_2, located near helices α1 and α10 (*15, 18*) (Fig. 4B) and

102   positions the phosphate of its ppant arm at the entrance of the C domain active site tunnel (fig. S2H).

103   This T_2 position agrees with our direct coupling analysis (*25*) (DCA) and that in AB3404 (*18*), but is

104   rotated by ~55° from that in surfactin synthetase (*15*) (fig. S7A-C, Table S2).

105   Four structures ($FAT_{fVal}C$, $FAT_{fVal}C^*$, FATCA, FATCAT) show T_1 binding to the donor site of

106   C_2 (Fig. 4B,C). This canonical T_n:C_{n+1} interaction is the functional link between modules 1 and 2,

107   which allows the nascent peptide to be elongated and passed downstream in the condensation reaction.

108   The donor site is a shallow depression between helices α4 and α9 on the opposite side of the C domain

109   tunnel from the acceptor site (Fig. 4B). Each LgrA donor structure has slightly different residue-level

110 $T_1:C_2$ contacts, all dominated by van der Waals interactions, which shift distal T_1 residues up to ~3.5 Å

111 (Fig 4B, fig. S7D,E). DCA of the $T_n:C_{n+1}$ interaction showed strong co-evolution signal between the

112 areas of T_1 and C_2 we observe in direct contact (Fig. 4C, Table S3). We established a multiple-turnover

113 peptide synthesis assay by fusing FATCAT to the terminal C (C_T) domain of bacillamide synthetase,

114 which catalyzes peptide release by condensation with free tryptamine (Tpm) (*26, 27*). "Wild type"

115 FATCAT-C_T produces fVal-Gly-Tpm tripeptide (Fig. 4D). We then used DCA, whose capacity to

116 predict mutational effects in proteins has recently been established (*28*), to guide mutational analysis of

117 the $T_1:C_2$ interface. Of four mutations in C_2 predicted to be deleterious for the $T_1:C_2$ interaction but not

118 for C_2 folding, three showed moderate but significant decrease in tripeptide production (Fig. 4E, fig.

119 S7J-M). The observed binding is thus likely a faithful representation of an important $T_1:C_2$ interaction.

120 T domains have previously been observed bound to sites analogous to the donor site in

121 specialized C domain homologues: E domains, found downstream of T domains in some modules,

122 catalyze chirality inversion in the peptide intermediate (*29*). Fungal NRPSs often end with a terminal

123 condensation-like (C_t) domain, which catalyzes peptide release by macrocyclization with an internal

124 nucleophile in the peptide intermediate (*30*). Both E and C_t domains have evolutionarily diverged from

125 canonical C domains (*5, 31*), and each has one only T domain binding site, which is analogous to the

126 donor site. The structure of TqaA didomain T_3C_t (*30*) shows contacts clustered on the α9 side of the

127 donor site depression, similar to our $T_1:C_2$ interaction, with T_3 shifted by maximally ~7 Å (fig. S7G).

128 However, the position of T_1 in the structure of the GrsA didomain T_1E_1 (*29*) is quite different, rotated

129 by ~37° and translated ~13 Å to the α4 side of the donor site (fig. S7F). Correspondingly, DCA

130 between T_n and E_n domains (within $C_nA_nT_nE_n$ modules) shows signal clustered on that α4 side (fig.

131 S7I, Table S4). T domains thus bind C and E domains in distinct ways, with our structures and TqaA

132 TC_t representing $T_n:C_{n+1}$ binding, and the GrsA didomain representing $T_n:E_n$ binding.

133   T domain binding to the donor site places the ppant arm into that side of the active site tunnel.

134   The tunnel leads to the C domain's conserved HHxxxDG catalytic motif, with the second histidine

135   (His908) most important for activity (*32-34*). $FAT_{fVal}C$, $FAT_{fVal}C^*$ and FATCA all show electron

136   density for the (amino-)ppant (*35*) arm in the C_2 tunnel (Fig. 4F, fig. S2C, E, F). $FAT_{fVal}C$ contains

137   extra density attached to the amino-ppant which fits fVal (fig. S2E, F), placing the formyl group within

138   hydrogen bonding distance of Tyr810 (Fig. 4G). The donor ppant-fVal would require a small shift of

139   the Val to expose the reactive carbonyl carbon to the acceptor site (Fig. 4G), which may only occur

140   when acceptor substrate binds to the active site. A transient "opening" or "closing" of the V shape

141   formed by the C domain's N- and C-lobes (*5, 34*) could also be involved, though C_2 is in very similar

142   conformations in all the structures, not greatly influenced by whether the T domains are interacting

143   with C_2 or what is attached to the ppants (fig. S6). The small shift of a donor substrate to achieve a

144   fully reactive conformation is reminiscent of the large ribosomal subunit, which maintains peptidyl-

145   tRNA in a non-reactive conformation until the aminoacyl-tRNA binds (*36*).

146

147   *Dimodular conformations and the scale of conformational changes*

148   FATCAT, FATCA and both molecules of $FAT_{Vad}CA$ provide insight into questions of super-

149   modular architecture. In FATCAT and FATCA, T_1 is similarly bound at the donor site of C_2, but A_2 or

150   A_2T_2 is folded back towards the initiation module in two distinctive ways (Fig. 5A): In FATCAT (and

151   also in $FAT_{fVal}C$ and $FAT_{fVal}C^*$), C_2 makes contact with F_1 near its active site. In contract, the entire

152   second module in FATCA is rotated ~114° around the F_1A_1 didomain, the C_2A_{2core} didomain center of

153   mass is translocated by ~80 Å (Fig. 5A) and C_2 makes extensive contacts with A_1. Notably, the C_2

154   acceptor site is not obstructed by any of these interactions, meaning this conformation would allow a

155   full condensation state in solution. Thus the overall conformations of FATCAT and FATCA are very

156   different, but both seem capable of peptide bond formation.

157   To obtain the crystals of $FAT_{Vad}CA$, we used a valinyl-adenosine-vinylsulfamonamide (Vad)

158   dead-end inhibitor of the thiolation reaction (Fig 1A) (*37, 38*). Vad binds A_1 and allows the

159   nucleophilic attack of ppant-T_1 on Vad, but is not cleaved by the reaction, tethering T_1 to Vad and

160   stalling T_1 and A_1 in the thiolation state. Fortuitously, the crystals of $FAT_{Vad}CA$ contain two molecules

161   in the asymmetric unit, revealing two different views of the complex. In both molecules, Vad is indeed

162   at the A_1 active site and T_1 and A_{1sub} are in thiolation conformation, but the elongation module has

163   remarkably different orientations. In one molecule, C_2A_2 extends away from $F_1A_1T_1$ at ~45° (Figs. 2E,

164   5B), and in the other it makes a ~135° angle on a different axis (Figs. 2D, 5B). The transition between

165   the two conformations would require a ~82 Å translation and ~140° rotation of the C_2A_2 (Fig. 5B). The

166   initiation and elongation modules do not form substantial interactions with each other in either

167   conformation, with the T_1-C_2 linker acting as a flexible tether between the two modules.

168   Comparing the four dimodular conformations observed in our structures shows dramatically the

169   scale of the conformational changes possible in a dimodular NRPS. Residues on the distal side of A_{2core}

170   would move by between 85 Å and 216 Å to transition between observed conformations. This is similar

171   to the length of the full dimodular NRPS, as the longest distance within any structure is 220 Å. The

172   kinds of conformational changes required for these transitions is presented in Movie S1.

173   To assess whether the conformational variability seen in the crystal structures reflected

174   flexibility in solution, we analyzed the behavior of FATCA, the LgrA construct in three of the four

175   different crystallographic-observed conformations, using small angle X-ray scattering (SAXS).

176   $FAT_{Vad}CA$, $FAT_{fVal}CA$ and apo-FATCA samples behaved well in solution as judged by the initial

177   characterization of their scattering curves (Fig. S8). Notably, their pair-distance distribution functions

178   had limited features and large Dmax values (fig. S8K-M), which is a characteristic of molecules that

179   either adopt extended conformations or are flexible (*39*). Comparison of the experimental scattering

180   curves to theoretical scattering curves calculated from the crystal structures resulted in very poor fits

181   (fig. S9, Table S6), indicating that none of the individual conformations observed in the crystal

182 structures fully described the conformation of FATCA in solution. Using weighted combinations of the

183 crystal structures improved the χ^2 values somewhat (Table S7) (*40*). Modelling of the scattering curves

184 using the multiple ensemble optimization method (*41*) resulted in ensembles with excellent fits (fig.

185 S9D-F). The ensembles were reminiscent of the series of conformations observed in the crystal

186 structures (fig. S9G-J) and retained a level of flexibility similar to the original pool of 1000

187 independent models (Table S5), consistent with the interpretation that LgrA is highly flexible.

188

189 *Structures and sequence statistics enable module swapping bioengineering*

190   The structures and SAXS suggest that there is little constraint on positions of adjacent modules

191 in NRPSs. Other than the intramodular linker, only the condensation reaction and the T_1:C_2 interaction

192 during this reaction strictly couple neighbouring modules. Thus, high-resolution views of the T_1:C_2

193 interaction should enable module swapping experiments. We fused module 1 of LgrA (LgrA$_{M1}$) with

194 the termination module 4 in cereulide synthetase (CesB$_{M4}$) to produce a chimera which synthesizes

195 fVal-Val (Fig. 6, fig. S10). We then used DCA to guide mutagenesis of the T_1:C_{CesB-4} interface aimed

196 at increasing activity of the chimera. Mutations in C_{CesB-4} rather than T_1 were targeted because T_1 must

197 interact with F_1, A_1 and C_{CesB-4} for synthesis, but the donor site of C_{CesB-4} must interact only with T_1.

198 Saturation mutagenesis *in silico* of 75 residues around the donor site of C_{CesB-4} was performed and five

199 mutations predicted to improve T:C interaction without substantially affecting C domain folding were

200 constructed and tested *in vitro* (Fig. 6B, Table S8). Three of the mutations decreased activity (Fig. 6C),

201 but E925A and H1008Q showed a significant increase in fVal-Val formation (Fig. 6D). DCA scores

202 predicted that effects of C domain mutations should be additive; LgrA$_{M1}$-CesB$_{M4}$(E925A, H1008Q) did

203 indeed show an additive effect, doubling the peptide production of the LgrA$_{M1}$-CesB$_{M4}$ chimera.

204

205 **Discussion**

206   The series of structures and SAXS data presented portray multimodular NRPSs as very flexible.

207   Previous results showed that within a single module, the catalytic state can define the positions of all

208   domains in the module (e.g., the thiolation state has specific positions of all domains in an initiation or

209   elongation module) (*15, 17, 18*). In contrast, our current structures suggest that for multi-modular

210   NRPSs, there is no strict coupling between the catalytic state of a particular module and the overall

211   conformation of the multimodular NRPS. Rather, it appears that many overall conformations can allow

212   the various catalytic states: $FAT_{Vad}CA$ molecule 1, $FAT_{Vad}CA$ molecule 2, and a continuum of

213   unobserved other conformations should allow thiolation; FATCA, FATCAT and a continuum of

214   unobserved conformations should allow condensation. The continuum of conformations need not be

215   equally populated: The observation of the same condensation conformation in multiple crystal forms

216   hints it may be more common than others. Each conformation we observed was fortuitously selected

217   through crystallization in the very different packing environments of the five unrelated crystal forms.

218   Inspection of the crystal packing reveals a myriad of different crystal contacts and few trends, though

219   perhaps predictably, many more contacts are mediated by the larger domains/subdomains (F, A_{cores}, C)

220   than the small, mobile ones (A_{sub}, T), and the lower diffracting crystal forms have more porous packing

221   and spacious solvent channels.

222   The four conformations we observe are all markedly different from each other, and none of the

223   observed positions of module 2 would allow module 1 to perform each step of its catalytic cycle. (For

224   example, module 2 has to move from any observed positions to allow T_1 to reach the F_1 active site.) To

225   test if there is a single overall dimodule conformation that is compatible with the full synthetic cycle,

226   we visualized possible positions of module 2 by drawing spheres with radii of the length of the T_1-C_2

227   linker, at the observed positions of the last residue of T_1. In FATCAT, as well as in an extrapolated

228   CATCAT dimodule, there is little or no available position within the overlapping spheres (fig. S11).

229   These volume constraints, combined with the lack of any detectable $C_nA_n : C_{n+1}A_{n+1}$ co-evolution,

230   make it likely no static module:module conformation exists that accommodates the full NRPS synthetic

231 cycle. Although it is possible that some NRPSs have a different nature from LgrA, we suggest NRPSs

232 in general do not possess constant and rigid super-modular architecture.

233   The high flexibility of NRPSs could facilitate synthetic cycles that include co-synthetic

234 modification (tailoring), are non-canonical or are non-linear. Flexibility could be important for NRPSs

235 with tailoring domains inserted at different positions in their architecture (*17, 42*) or NRPSs with an

236 abnormal order of domains, like heterobactin synthetase (which includes a C-T-A module) (*43*),

237 obafluorin synthetase (which has an A domain C-terminal to its TE domain) (*44, 45*), or vibriobactin

238 synthetase (which includes VibF: Cy-Cy-A-C-T-C) (*46*). Equally unusual systems include: beauvericin

239 synthetase, which uses tandem T domains to perform iterative condensation (*47*); myxochromides S1-3

240 synthetase, which performs skipping of module 4, with T_3 donating the peptide directly to module 5

241 (*48*); thalassospiramide B synthetase, where A_2 is proposed to thiolate T_1, T_2 and T_5 (*49*). Presumably

242 some of these specialized systems have additional interactions that bring domains which are far apart in

243 sequence, close together in space.

244   Because of their straightforward synthetic logic and important bioactive products, NRPSs have

245 long been the subject of bioengineering attempts to create new-to-nature peptides, with mixed success

246 (*50, 51*). Strategies include mutation of the A domain substrate binding pocket (*52, 53*), domain swaps

247 (*54*), module deletion or insertion (*55, 56*), module swaps (*54*), swaps of module-sized segments (*57-*

248 *59*) and multi-modular swaps via docking domains (*60, 61*). This includes interesting recent results

249 using swapped $A_nT_nC_{n+1}$ segments (*57, 58*), a strategy that conserves the native donor $T_n:C_{n+1}$

250 interaction but not the acceptor $C_n:T_n$ interaction (*57, 58*), and using the junction of the N and C lobe of

251 the C domain as the split point (*58, 59*). Notably, both the N and C lobes contribute to both the donor

252 and the acceptor T domain binding sites.

253   The lack of strong interactions between the didomain structural units of adjacent modules

254 observed here should facilitate module swapping experiments, but unnatural $T_n:C_{n+1}$ interactions could

255 inhibit synthesis. That we increased the activity of a chimera by improving the unnatural $T_1:C_2$

12

256   interaction indicates that this interaction can be rate-limiting in module-swapped NRPSs. Although it

257   did not produce orders of magnitude higher product quantity, our approach for improving unnatural

258    $T_n:C_{n+1}$ interactions could be combined with other bioengineering strategies, and may help NRPSs

259   fulfill their long-held promise as sources of novel designer bioactive small molecules.

260

261   **Materials and methods summary**

262   Constructs were cloned with cleavable octa-histidine and calmodulin binding peptide tags and

263   modified by site-directed mutagenesis. Proteins were expressed in *E.coli* and purified for crystallization

264   by calmodulin affinity, nickel affinity, tag removal, anion exchange and gel filtration chromatography.

265   FATCAT-C_T and LgrA$_{M1}$-CesB$_{M4}$ were purified by calmodulin affinity, nickel affinity and gel

266   filtration. Ppants were added to apo T domains using Sfp and fVal-NH-CoA or CoA. Valinyl-

267   adenosine-vinylsulfamonamide was complexed to FATCA by including it in the Sfp reaction.

268   Initial nano-volume crystallization conditions were optimized in large format to the conditions

269   listed in Supplemental Materials. FATC was phased by MR in Phenix (*62*) with FA$_{core}$ (*17*) and the N-

270   lobe of TycC (PDB 2JGP) (*10*), followed by (re)building in Coot (*63*) and refinement in Phenix.

271   Models of F, A$_{1core}$ and C and homology models A$_2$ and T$_2$ were used for MR phasing or as a starting

272   point for (re)building and refinement for other structures.

273   Small angle scattering data were collected at three concentrations and processed using ATSAS

274   (*40*). Because of evidence of high flexibility, EOM2 (*41*) was used to generate ensembles of FATCA

275   conformations whose theoretical combined scattering matches well the experimentally measured

276   scattering.

277   For peptide synthesis by FATCAT-C_{T3}, 3.7 µM protein was incubated with 0.2 mM N10-fTHF,

278   5 mM valine, 2 mM glycine, 1 mM tryptamine, 5 mM ATP at 23 °C for 5 h prior to quenching and LC-

279   MS. For peptide synthesis by LgrA$_{M1}$-CesB$_{M4}$, 5 µM protein was incubated with 5 mM valine, 5 mM

280   ATP and 0.5 mM N10-fTHF for 6 h prior to quenching and LC-MS.

281   For DCA (*64*), we extracted 45,015 T$_n$:C$_{n+1}$ pairs, 14,506 T$_n$:E$_n$ pairs and 29,700 C$_n$:T$_n$ pairs and

282   calculated interdomain contact scores and domain-domain interaction scores. To computationally

283   suggest mutations to improve the T$_n$:C$_{n+1}$ interaction, we altered all single amino acids in C$_{n+1}$ interface

284   positions to all 19 other amino acids and evaluated the interaction scores, looking for those that

285   improve the T$_n$:C$_{n+1}$ interaction score and do not affect substantially the C domain score.

286

287   **Supplementary materials**

288   Detailed Materials and Methods

289   Figs. S1 to S11

290   Tables S1 to S10

291   Supplemental References 65-89

292   Movie S1

293   **References**

294   1.   C. T. Walsh, Polyketide and nonribosomal peptide antibiotics: modularity and versatility.

295   *Science* **303**, 1805-1810 (2004).

296   2.   E. A. Felnagle *et al.*, Nonribosomal peptide synthetases involved in the production of medically

297   relevant natural products. *Mol Pharm* **5**, 191-211 (2008).

298   3.   N. A. McGrath, M. Brichacek, J. T. Njardarson, A Graphical Journey of Innovative Organic

299   Architectures That Have Improved Our Lives. *J Chem Educ* **87**, 1348-1349 (2010).

300   4.   J. M. Reimer, A. S. Haque, M. J. Tarry, T. M. Schmeing, Piecing together nonribosomal

301   peptide synthesis. *Curr Opin Struct Biol* **49**, 104-113 (2018).

302   5.   K. Bloudoff, T. M. Schmeing, Structural and functional aspects of the nonribosomal peptide

303   synthetase condensation domain superfamily: discovery, dissection and diversity. *Biochimica et*

304   *biophysica acta* **1865**, 1587-1604 (2017).

305   6.   G. H. Hur, C. R. Vickery, M. D. Burkart, Explorations of catalytic domains in non-ribosomal

306   peptide synthetase enzymology. *Nat Prod Rep* **29**, 1074-1098 (2012).

307   7.   C. T. Walsh *et al.*, Tailoring enzymes that modify nonribosomal peptides during and after chain

308   elongation on NRPS assembly lines. *Curr Opin Chem Biol* **5**, 525-534 (2001).

309   8.   K. J. Weissman, The structural biology of biosynthetic megaenzymes. *Nat Chem Biol* **11**, 660-

310   670 (2015).

311   9.   C. Chiocchini, U. Linne, T. Stachelhaus, In vivo biocombinatorial synthesis of lipopeptides by

312   COM domain-mediated reprogramming of the surfactin biosynthetic complex. *Chem Biol* **13**,

313   899-908 (2006).

314   10.   S. A. Samel, G. Schoenafinger, T. A. Knappe, M. A. Marahiel, L. O. Essen, Structural and

315   functional insights into a peptide bond-forming bidomain from a nonribosomal peptide

316   synthetase. *Structure* **15**, 781-792 (2007).

317   11.   M. J. Tarry, A. S. Haque, K. H. Bui, T. M. Schmeing, X-Ray Crystallography and Electron

318   Microscopy of Cross- and Multi-Module Nonribosomal Peptide Synthetase Proteins Reveal a

319   Flexible Architecture. *Structure* **25**, 783-793 e784 (2017).

320   12.   M. A. Marahiel, A structural model for multimodular NRPS assembly lines. *Nat Prod Rep* **33**,

321   136-140 (2016).

322   13.   G. Schoenafinger, N. Schracke, U. Linne, M. A. Marahiel, Formylation domain: an essential

323   modifying enzyme for the nonribosomal biosynthesis of linear gramicidin. *J Am Chem Soc* **128**,

324   7406-7407 (2006).

325   14.   B. A. Wallace, Common structural features in gramicidin and other ion channels. *Bioessays* **22**,

326   227-234 (2000).

327   15.   A. Tanovic, S. A. Samel, L. O. Essen, M. A. Marahiel, Crystal structure of the termination

328   module of a nonribosomal peptide synthetase. *Science* **321**, 659-663 (2008).

329   16.   J. M. Reimer, M. N. Aloise, H. R. Powell, T. M. Schmeing, Manipulation of an existing crystal

330   form unexpectedly results in interwoven packing networks with pseudo-translational symmetry.

331   *Acta Crystallogr D Biol Crystallogr* **72**, 1130-1136 (2016).

332   17.   J. M. Reimer, M. N. Aloise, P. M. Harrison, T. M. Schmeing, Synthetic cycle of the initiation

333   module of a formylating nonribosomal peptide synthetase. *Nature* **529**, 239-242 (2016).

334   18.   E. J. Drake *et al.*, Structures of two distinct conformations of holo-non-ribosomal peptide

335   synthetases. *Nature* **529**, 235-238 (2016).

336   19.   B. R. Miller, E. J. Drake, C. Shi, C. C. Aldrich, A. M. Gulick, Structures of a Nonribosomal

337   Peptide Synthetase Module Bound to MbtH-like Proteins Support a Highly Dynamic Domain

338   Architecture. *J Biol Chem* **291**, 22559-22571 (2016).

339   20.   J. Alfermann *et al.*, FRET monitoring of a nonribosomal peptide synthetase. *Nat Chem Biol* **13**,

340   1009-1015 (2017).

341   21.   K. Bloudoff, D. Rodionov, T. M. Schmeing, Crystal structures of the first condensation domain

342   of CDA synthetase suggest conformational changes during the synthetic cycle of nonribosomal

343   peptide synthetases. *J Mol Biol* **425**, 3137-3150 (2013).

344   22.   A. S. Reger, R. Wu, D. Dunaway-Mariano, A. M. Gulick, Structural characterization of a 140

345   degrees domain movement in the two-step reaction catalyzed by 4-chlorobenzoate:CoA ligase.

346   *Biochemistry* **47**, 8016-8025 (2008).

347   23.   C. A. Mitchell, C. Shi, C. C. Aldrich, A. M. Gulick, Structure of PA1221, a nonribosomal

348   peptide synthetase containing adenylation and peptidyl carrier protein domains. *Biochemistry*

349   **51**, 3252-3263 (2012).

350   24.   A. M. Gulick, Structural insight into the necessary conformational changes of modular

351   nonribosomal peptide synthetases. *Curr Opin Chem Biol* **35**, 89-96 (2016).

352 25. F. Morcos *et al.*, Direct-coupling analysis of residue coevolution captures native contacts across

353 many protein families. *Proc Natl Acad Sci U S A* **108**, E1293-1301 (2011).

354 26. L. Yuwen *et al.*, The role of aromatic L-amino acid decarboxylase in bacillamide C

355 biosynthesis by Bacillus atrophaeus C89. *Sci Rep* **3**, 1753 (2013).

356 27. K. Bloudoff, C. D. Fage, M. A. Marahiel, T. M. Schmeing, Structural and mutational analysis

357 of the nonribosomal peptide synthetase heterocyclization domain provides insight into catalysis.

358 *Proc Natl Acad Sci U S A* **114**, 95-100 (2017).

359 28. M. Figliuzzi, H. Jacquier, A. Schug, O. Tenaillon, M. Weigt, Coevolutionary Landscape

360 Inference and the Context-Dependence of Mutations in Beta-Lactamase TEM-1. *Mol Biol Evol*

361 **33**, 268-280 (2016).

362 29. W.-H. Chen, K. Li, N. S. Guntaka, S. D. Bruner, Interdomain and Intermodule Organization in

363 Epimerization Domain Containing Nonribosomal Peptide Synthetases. *ACS chemical biology*

364 **11**, 2293-2303 (2016).

365 30. J. Zhang *et al.*, Structural basis of nonribosomal peptide macrocyclization in fungi. *Nat Chem*

366 *Biol* **12**, 1001-1003 (2016).

367 31. C. Rausch, I. Hoof, T. Weber, W. Wohlleben, D. H. Huson, Phylogenetic analysis of

368 condensation domains in NRPS sheds light on their functional evolution. *BMC Evol Biol* **7**, 78

369 (2007).

370 32. C. Y. Chang *et al.*, Structural Insights into the Free-Standing Condensation Enzyme SgcC5

371 Catalyzing Ester-Bond Formation in the Biosynthesis of the Enediyne Antitumor Antibiotic C-

372 1027. *Biochemistry* **57**, 3278-3288 (2018).

373 33. V. Bergendahl, U. Linne, M. A. Marahiel, Mutational analysis of the C-domain in nonribosomal

374 peptide synthesis. *Eur J Biochem* **269**, 620-629 (2002).

375 34. K. Bloudoff, D. A. Alonzo, T. M. Schmeing, Chemical Probes Allow Structural Insight into the

376 Condensation Reaction of Nonribosomal Peptide Synthetases. *Cell Chem Biol* **23**, 331-339

377 (2016).

378 35. Y. Liu, S. D. Bruner, Rational manipulation of carrier-domain geometry in nonribosomal

379 peptide synthetases. *Chembiochem* **8**, 617-621 (2007).

380 36. T. M. Schmeing, K. S. Huang, S. A. Strobel, T. A. Steitz, An induced-fit mechanism to promote

381 peptide bond formation and exclude hydrolysis of peptidyl-tRNA. *Nature* **438**, 520-524 (2005).

382 37. C. Qiao, D. J. Wilson, E. M. Bennett, C. C. Aldrich, A mechanism-based aryl carrier

383 protein/thiolation domain affinity probe. *J Am Chem Soc* **129**, 6350-6351 (2007).

384 38. J. A. Sundlov, C. Shi, D. J. Wilson, C. C. Aldrich, A. M. Gulick, Structural and functional

385 investigation of the intermolecular interaction between NRPS adenylation and carrier protein

386 domains. *Chem Biol* **19**, 188-198 (2012).

387 39. P. Bernado, Effect of interdomain dynamics on the structure determination of modular proteins

388 by small-angle scattering. *Eur Biophys J* **39**, 769-780 (2010).

389 40. D. Franke *et al.*, ATSAS 2.8: a comprehensive data analysis suite for small-angle scattering

390 from macromolecular solutions. *Journal of Applied Crystallography* **50**, 1212-1225 (2017).

391 41. G. Tria, H. D. Mertens, M. Kachala, D. I. Svergun, Advanced ensemble modelling of flexible

392 macromolecules using X-ray solution scattering. *IUCrJ* **2**, 207-217 (2015).

393 42. S. Mori *et al.*, Structural basis for backbone N-methylation by an interrupted adenylation

394 domain. *Nature Chemical Biology*, (2018).

395 43. M. Bosello *et al.*, Structural Characterization of the Heterobactin Siderophores from

396 Rhodococcus erythropolis PR4 and Elucidation of Their Biosynthetic Machinery. *Journal of*

397 *Natural Products* **76**, 2282-2290 (2013).

398 44. J. E. Schaffer, M. R. Reck, N. K. Prasad, T. A. Wencewicz, beta-Lactone formation during

399 product release from a nonribosomal peptide synthetase. *Nat Chem Biol* **13**, 737-744 (2017).

400 45. D. F. Kreitler, E. M. Gemmell, J. E. Schaffer, T. A. Wencewicz, A. M. Gulick, The structural

401   basis of N-acyl-alpha-amino-beta-lactone formation catalyzed by a nonribosomal peptide

402   synthetase. *Nature communications* **10**, 3432 (2019).

403 46. N. J. Hillson, C. T. Walsh, Dimeric structure of the six-domain VibF subunit of vibriobactin

404   synthetase: mutant domain activity regain and ultracentrifugation studies. *Biochemistry* **42**, 766-

405   775 (2003).

406 47. Y. Xu *et al.*, Biosynthesis of the cyclooligomer depsipeptide beauvericin, a virulence factor of

407   the entomopathogenic fungus Beauveria bassiana. *Chem Biol* **15**, 898-907 (2008).

408 48. S. C. Wenzel *et al.*, Structure and biosynthesis of myxochromides S1-3 in Stigmatella

409   aurantiaca: evidence for an iterative bacterial type I polyketide synthase and for module

410   skipping in nonribosomal peptide biosynthesis. *Chembiochem* **6**, 375-385 (2005).

411 49. A. C. Ross *et al.*, Biosynthetic multitasking facilitates thalassospiramide structural diversity in

412   marine bacteria. *J Am Chem Soc* **135**, 1155-1162 (2013).

413 50. M. Winn, J. K. Fyans, Y. Zhuo, J. Micklefield, Recent advances in engineering nonribosomal

414   peptide assembly lines. *Nat Prod Rep* **33**, 317-347 (2016).

415 51. A. S. Brown, M. J. Calcott, J. G. Owen, D. F. Ackerley, Structural, functional and evolutionary

416   perspectives on effective re-engineering of non-ribosomal peptide synthetase assembly lines.

417   *Nat Prod Rep*, (2018).

418 52. K. Eppelmann, T. Stachelhaus, M. A. Marahiel, Exploitation of the selectivity-conferring code

419   of nonribosomal peptide synthetases for the rational design of novel peptide antibiotics.

420   *Biochemistry* **41**, 9718-9726 (2002).

421 53. J. Thirlway *et al.*, Introduction of a non-natural amino acid into a nonribosomal peptide

422   antibiotic by modification of adenylation domain specificity. *Angew Chem Int Ed Engl* **51**,

423   7181-7184 (2012).

424 54. K. T. Nguyen *et al.*, Combinatorial biosynthesis of novel antibiotics related to daptomycin.

425 *Proc Natl Acad Sci U S A* **103**, 17462-17467 (2006).

426 55. H. D. Mootz *et al.*, Decreasing the ring size of a cyclic nonribosomal peptide antibiotic by in-

427 frame module deletion in the biosynthetic genes. *J Am Chem Soc* **124**, 10980-10981 (2002).

428 56. D. Butz *et al.*, Module extension of a non-ribosomal peptide synthetase of the glycopeptide

429 antibiotic balhimycin produced by Amycolatopsis balhimycina. *Chembiochem* **9**, 1195-1200

430 (2008).

431 57. K. A. J. Bozhuyuk *et al.*, De novo design and engineering of non-ribosomal peptide synthetases.

432 *Nat Chem* **10**, 275-281 (2018).

433 58. C. Steiniger *et al.*, Harnessing fungal nonribosomal cyclodepsipeptide synthetases for

434 mechanistic insights and tailored engineering. *Chem Sci* **8**, 7834-7843 (2017).

435 59. K. A. J. Bozhüyük *et al.*, Modification and de novo design of non-ribosomal

436 peptide synthetases (NRPS) using specific assembly points within condensation domains.

437 *bioRxiv*, 354670 (2018).

438 60. M. Hahn, T. Stachelhaus, Harnessing the potential of communication-mediating domains for

439 the biocombinatorial synthesis of nonribosomal peptides. *Proc Natl Acad Sci U S A* **103**, 275-

440 280 (2006).

441 61. C. Hacker *et al.*, Structure-based redesign of docking domain interactions modulates the

442 product spectrum of a rhabdopeptide-synthesizing NRPS. *Nature communications* **9**, 4366

443 (2018).

444 62. P. D. Adams *et al.*, PHENIX: building new software for automated crystallographic structure

445 determination. *Acta Crystallogr D Biol Crystallogr* **58**, 1948-1954 (2002).

446 63. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. *Acta*

447 *Crystallogr D Biol Crystallogr* **66**, 486-501 (2010).

448   64.   M. Weigt, R. A. White, H. Szurmant, J. A. Hoch, T. Hwa, Identification of direct residue

449   contacts in protein-protein interaction by message passing. *Proc Natl Acad Sci U S A* **106**, 67-

450   72 (2009).

451   65.   D. A. Alonzo, N. A. Magarvey, T. M. Schmeing, Characterization of cereulide synthetase, a

452   toxin-producing macromolecular machine. *PLoS One* **10**, e0128569 (2015).

453   66.   C. Chalut, L. Botella, C. de Sousa-D'Auria, C. Houssin, C. Guilhot, The nonredundant roles of

454   two 4'-phosphopantetheinyl transferases in vital processes of Mycobacteria. *Proc Natl Acad Sci*

455   *U S A* **103**, 8511-8516 (2006).

456   67.   B. A. Pfeifer, S. J. Admiraal, H. Gramajo, D. E. Cane, C. Khosla, Biosynthesis of complex

457   polyketides in a metabolically engineered strain of E. coli. *Science* **291**, 1790-1792 (2001).

458   68.   A. S. Worthington, M. D. Burkart, One-pot chemo-enzymatic synthesis of reporter-modified

459   proteins. *Org Biomol Chem* **4**, 44-46 (2006).

460   69.   L. E. Quadri *et al.*, Characterization of Sfp, a Bacillus subtilis phosphopantetheinyl transferase

461   for peptidyl carrier protein domains in peptide synthetases. *Biochemistry* **37**, 1585-1595 (1998).

462   70.   A. G. W. Leslie, H. R. Powell, Processing diffraction data with MOSFLM. *Nato Sci Ser Ii Math*

463   **245**, 41-51 (2007).

464   71.   G. Winter *et al.*, DIALS: implementation and evaluation of a new integration package. *Acta*

465   *Crystallogr D Struct Biol* **74**, 85-97 (2018).

466   72.   P. R. Evans, G. N. Murshudov, How good are my data and what is the resolution? *Acta*

467   *Crystallogr D Biol Crystallogr* **69**, 1204-1214 (2013).

468   73.   A. J. McCoy *et al.*, Phaser crystallographic software. *J Appl Crystallogr* **40**, 658-674 (2007).

469   74.   G. Bunkoczi, R. J. Read, Improvement of molecular-replacement models with Sculptor. *Acta*

470   *Crystallogr D Biol Crystallogr* **67**, 303-312 (2011).

471   75.   A. T. Brunger, Version 1.2 of the crystallography and NMR system. *Nat Protoc* **2**, 2728-2733

472   (2007).

473   76.   M. Biasini *et al.*, SWISS-MODEL: modelling protein tertiary and quaternary structure using

474   evolutionary information. *Nucleic Acids Res* **42**, W252-258 (2014).

475   77.   N. W. Moriarty, R. W. Grosse-Kunstleve, P. D. Adams, electronic Ligand Builder and

476   Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. *Acta*

477   *Crystallogr D Biol Crystallogr* **65**, 1074-1080 (2009).

478   78.   S. D. Breazeale, A. A. Ribeiro, C. R. Raetz, Oxidative decarboxylation of UDP-glucuronic acid

479   in extracts of polymyxin-resistant Escherichia coli. Origin of lipid a species modified with 4-

480   amino-4-deoxy-L-arabinose. *J Biol Chem* **277**, 2886-2896 (2002).

481   79.   G. L. Hura *et al.*, Robust, high-throughput solution structural analyses by small angle X-ray

482   scattering (SAXS). *Nat Methods* **6**, 606-612 (2009).

483   80.   K. N. Dyer *et al.*, High-throughput SAXS for the characterization of biomolecules in solution: a

484   practical approach. *Methods Mol Biol* **1091**, 245-258 (2014).

485   81.   S. Classen *et al.*, Implementation and performance of SIBYLS: a dual endstation small-angle X-

486   ray scattering and macromolecular crystallography beamline at the Advanced Light Source. *J*

487   *Appl Crystallogr* **46**, 1-13 (2013).

488   82.   P. V. Konarev, V. V. Volkov, A. V. Sokolova, M. H. J. Koch, D. I. Svergun, PRIMUS: a

489   Windows PC-based system for small-angle scattering data analysis. *Journal of Applied*

490   *Crystallography* **36**, 1277-1282 (2003).

491   83.   D. Svergun, C. Barberato, M. H. J. Koch, CRYSOL - A program to evaluate x-ray solution

492   scattering of biological macromolecules from atomic coordinates. *Journal of Applied*

493   *Crystallography* **28**, 768-773 (1995).

494   84.   R. D. Finn *et al.*, The Pfam protein families database: towards a more sustainable future.

495   *Nucleic Acids Res* **44**, D279-285 (2016).

496   85.   S. R. Eddy, Accelerated Profile HMM Searches. *PLoS Comput Biol* **7**, e1002195 (2011).

497 86. C. The UniProt, UniProt: the universal protein knowledgebase. *Nucleic Acids Res* **45**, D158-

498 D169 (2017).

499 87. N. Ziemert *et al.*, The natural product domain seeker NaPDoS: a phylogeny based bioinformatic

500 tool to classify secondary metabolite gene diversity. *PLoS One* **7**, e34064 (2012).

501 88. M. Ekeberg, C. Lovkvist, Y. Lan, M. Weigt, E. Aurell, Improved contact prediction in proteins:

502 using pseudolikelihoods to infer Potts models. *Phys Rev E Stat Nonlin Soft Matter Phys* **87**,

503 012707 (2013).

504 89. A. Procaccini, B. Lunt, H. Szurmant, T. Hwa, M. Weigt, Dissecting the specificity of protein-

505 protein interaction in bacterial two-component signaling: orphans and crosstalks. *PLoS One* **6**,

506 e19729 (2011).

507

528

Figures


Figure 1

Figure 1. Overview of the biosynthetic steps performed by LgrA.

A, Linear gramicidin synthetase subunit A is a dimodular protein with initiation ($F_1A_1T_1$) and

elongation modules ($C_2A_2T_2E^o_2$). Valine and glycine are selected and adenylated by A_1 and A_2, and

then transferred to T_1 and T_2. Val-T_1 is formylated by F_1 and then peptide bond formation between

fVal-T_1 and Gly-T_2 by C_2 produces fVal-Gly-T_2. This is the donor substrate for peptide bond formation

in the C_3 domain of the next NRPS subunit, LgrB. (This schematic is not intended to indicate the

timing of rebinding of substrates.) **B**, Chemical structure of linear gramicidin A with a box highlighting

the fVal-Gly portion assembled by LgrA. F, formylation domain; A, adenylation domain; T, thiolation

domain; C, condensation domain; E^o, inactive epimerization domain.

24

Figure 2. Crystal structures of dimodular LgrA.

Structures of LgrA constructs **A**, $FAT_{fVal}C$, which has fVal-aminoppant on T_1 and is bound with valine, AMPcPP and fTHF (space group $P2_12_12_1$; 2.5 Å resolution), **B**, FATCA ($P2_12_12_1$; 2.5 Å resolution), **D,** **E**, two crystallographically-independent molecules of $FAT_{Vad}CA$, for which dead-end valinyl-adenosine-vinylsulfamonamide (Vad) were used to stall T_1 at A_1 during thiolation ($P2_12_12_1$; 6 Å resolution) **F**, **G**, FATCAT, which has ppant on both T domains ($C222_1$; 6 Å resolution). See fig S1A-B for additional structures. Cartoon insets: schematic depicting protein constructs crystallized. Domains which are greyed in the labels are disordered in the crystal structure

549 **Figure 3**

550 **Figure 3. Comparison of intramodular conformations.**

551 **A**, The structural unit for the initiation module (F_1A_{1core}) and **B,** elongation module (C_2A_{2core}) are in

552 similar conformations in all structures. The F_1:A_{1core} interface buries 773-860 $Å^2$ and the C_2:A_{2core}

553 interface buries 565-770 $Å^2$. Superimposing based A_{core} shows a ~1-12° shift of F_1 or C_2. Previously

554 EntF C_1:A_1 was seen to shift ~15° (*18*) between structures.

Figure 4

Figure 4. Condensation in LgrA.

A, FATCAT shows a full condensation state, with T_1 and T_2 docked at the donor and acceptor binding sites, respectively. $FAT_{fVal}C$ and $FAT_{fVal}C^*$ are overlayed to show that the first four domains are in analogous positions regardless of space group or resolution of the structures. **B**, Overlay of LgrA structures with T_1 at C_2. **C**, DCA between T_n and C_{n+1} displayed on LgrA; co-evolution signal (red lines) between residues in close proximity in the LgrA structures. Residues selected for mutation are indicated with brown α-carbon spheres. **D**, Schematic of the LgrA-BmdB chimera protein FATCAT-C_{T3} and its product fVal-Gly-Tpm. **E**, LC-MS peptide synthesis assay of mutations near the T_1 binding site of C_2. All reactions were performed in triplicate (n=3) and are shown as mean values from integration of extracted-ion-chromatogram (EIC) peaks, normalized against the average wild type value. Statistical significance was determined by two-sided student's t-test (ns: $p > 0.05$; *: $p \leq 0.05$;

27

567   **: $p \leq 0.01$; ***: $p \leq 0.001$; ****: $p \leq 0.0001$). **F**, Unbiased F_O-F_C (3σ) simulated annealing Polder

568   omit electron density map of the C_2 active site of FAT$_{fVal}$C, calculated with phases from model that

569   never included fVal-ppant ligand. **G**, Zoom in to the FAT$_{fVal}$C C_2 active site which shows that the Val

570   would rotate for condensation.

571   **Figure 5**

572   **Figure 5. Different dimodular conformations for the same catalytic states.**

573   **A,** FATCAT and FATCA both show T_1 binding to the donor site of C_2 but have very different overall

574   conformations. **B**, The two crystallographically-independent molecules of FAT$_{Vad}$CA both show

575   module 1 in thiolation conformation, but have very different positions of module 2. **C**, The distances

576   between positions of residue D1236 in the four dimodular conformations. The structures are

577   superimposed by their A$_{1core}$.

Figure 6. Module swapping bioengineering using structural and direct coevolution analysis.

A, Schematic of the LgrA_{M1}-CesB_{M4} chimera and its product fVal-Val. **B**, Scatter diagram of the

difference in C domain score against the difference in $T_n:C_{n+1}$ interaction score for the DCA analysis of

75 residues around the donor T domain binding site of CesB C_4 mutated to each of the other 19 amino

acids. CesB C_4 mutations in red were analyzed biochemically. **C**, The corresponding positions of these

five mutations in LgrA C_2. **D**, Wild type LgrA_{M1}-CesB_{M4} and mutant proteins were assayed for peptide

production by LC-MS. All reactions were performed in triplicate (n=3) and are shown as mean values

from integration of extracted-ion-chromatogram (EIC) peaks, normalized against the average wild type

value. Statistical significance was determined by two-sided student's t-test (ns: $p > 0.05$; *: $p \leq 0.05$;

**: $p \leq 0.01$; ***: $p \leq 0.001$; ****: $p \leq 0.0001$).